UY39104A - Compuestos y métodos para modular la expresión de scn1a - Google Patents

Compuestos y métodos para modular la expresión de scn1a

Info

Publication number
UY39104A
UY39104A UY0001039104A UY39104A UY39104A UY 39104 A UY39104 A UY 39104A UY 0001039104 A UY0001039104 A UY 0001039104A UY 39104 A UY39104 A UY 39104A UY 39104 A UY39104 A UY 39104A
Authority
UY
Uruguay
Prior art keywords
dysfunctions
compounds
methods
pharmaceutical compositions
modulate
Prior art date
Application number
UY0001039104A
Other languages
English (en)
Inventor
M Freier Susan
Jafar-nejad Paymaan
Frank Rigo
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of UY39104A publication Critical patent/UY39104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan compuestos, métodos y composiciones farmacéuticas para modular la proteína y/o ARN de SCN1A en una célula o sujeto. Tales compuestos, métodos y composiciones farmacéuticas son útiles para mejorar al menos un síntoma de una enfermedad encefalopática epiléptica o del desarrollo, tal como el síndrome de Dravet. Dichos síntomas incluyen convulsiones, muerte súbita inesperada en la epilepsia, estado epiléptico, retrasos en el comportamiento y el desarrollo, disfunciones del movimiento y el equilibrio, afecciones ortopédicas, disfunciones motoras y cognitivas, problemas de retraso en el lenguaje y el habla, disfunciones de integración visomotora, disfunciones de percepción visual, disfunciones ejecutivas, problemas de crecimiento y nutrición.
UY0001039104A 2020-02-28 2021-03-01 Compuestos y métodos para modular la expresión de scn1a UY39104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983555P 2020-02-28 2020-02-28
US202063085111P 2020-09-29 2020-09-29

Publications (1)

Publication Number Publication Date
UY39104A true UY39104A (es) 2021-08-31

Family

ID=77491960

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039104A UY39104A (es) 2020-02-28 2021-03-01 Compuestos y métodos para modular la expresión de scn1a

Country Status (6)

Country Link
US (1) US20230043648A1 (es)
EP (1) EP4110919A4 (es)
JP (1) JP2023515974A (es)
TW (1) TW202140788A (es)
UY (1) UY39104A (es)
WO (1) WO2021174036A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019239971A1 (en) * 2018-03-21 2020-09-03 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
IL310811A (en) * 2021-08-27 2024-04-01 Ionis Pharmaceuticals Inc Compounds and Methods for Modulating SCN1A Expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278991B (zh) * 2017-08-25 2022-04-01 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
US10758629B2 (en) * 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
EP3840733A4 (en) * 2018-08-20 2022-07-20 Rogcon, Inc. ANTISENSE OLIGONUCLEOTIDES DIRECTED TO SCN2A FOR THE TREATMENT OF SCN1A ENCEPHALOPATHIES
CA3159162A1 (en) * 2019-12-06 2021-06-10 Isabel AZNAREZ Antisense oligomers for treatment of conditions and diseases

Also Published As

Publication number Publication date
EP4110919A1 (en) 2023-01-04
EP4110919A4 (en) 2024-06-05
US20230043648A1 (en) 2023-02-09
JP2023515974A (ja) 2023-04-17
WO2021174036A1 (en) 2021-09-02
TW202140788A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
UY39104A (es) Compuestos y métodos para modular la expresión de scn1a
NI200700040A (es) Analogos de biaril piperazinil-piridina sustituidos
NO20080282L (no) Fremgangsmate for fremstilling av hydrokarboner innen dieselomrade
CR20110650A (es) Mezclas fungicidas
AR077042A1 (es) Metodo para tratar una composicion que contiene pirofiofitina
IN2015DN01022A (es)
CO2017012545A2 (es) Sulfonas tricíclicas como moduladores del receptor huérfano relacionado con retinoide gamma (rorγ)
GT201200099A (es) Derivados que contienen antraquinona como productos agricolas bioquimicos
US9682150B1 (en) Anti-aging nutritional supplement compositions for animals
ECSP13013012A (es) Análogos del ácido epoxieicosatrienoicos y métodos de preparación
BR112022020495A2 (pt) Composições compreendendo algas e métodos de uso das mesmas para aumentar a produção de produto animal
CU20090158A7 (es) Método para la producción de un tabaco altamente mutado productor de semillas
PE20141068A1 (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
CO2021013371A2 (es) Compuestos y métodos para reducir la expresión de kcnt1
RU2011124942A (ru) Применение кантаксантина и/или 25-он-d3 для улучшения выводимости домашней птицы
WO2012057946A3 (en) Fuel and base oil blendstocks from a single feedstock
UY30921A1 (es) Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s
Gigova et al. Significance of microalgae-grounds and areas
PE20211702A1 (es) Acidos grasos de cadena muy larga
PE20211699A1 (es) Composiciones insecticidas de diamida
CL2023000393A1 (es) Compuestos y métodos para modular el scn2a
AR121445A1 (es) Compuestos y métodos para modular la expresión de scn1a